German biotech firm CureVac has enrolled the first participant for a Phase 2b/3 clinical trial of its Covid-19 vaccine candidate, it said yesterday. The trial, which is relevant for regulatory approval, will assess the safety and efficacy in adults and is expected to include more than 35,000 participants in Europe and Latin America, it added in a statement. The study aims to demonstrate the efficacy of its vaccine candidate in preventing first episodes of confirmed cases of Covid-19 of any severity as well as preventing moderate to severe confirmed cases of Covid-19 in participants who have never been infected with SARS-CoV-2, CureVac said.